| Bioactivity | ST 1535 is a potent and orally active A2A adenosine receptor antagonist. ST 1535 shows antiparkinsonian activity and antitremorigenic effects. ST 1535 has the potential for the research of Parkinson’s disease[1][2]. |
| Invitro | ST 1535 (0-1000 nM) 抑制 CHO 细胞中 forskolin (HY-15371) 诱导的 cAMP 的形成，对 hA1, hA2A, hA2B, hA3 的 IC50 值分别为 510, 353, 950, >1000 nM[1]。 |
| In Vivo | ST 1535 (0, 5, 10 mg/kg; 口服) 拮抗 A2A 腺苷激动剂 CGS 21680 (HY-13201) (i.c.v.) 诱发的僵直症[1]。ST 1535 (10、20、40 mg/kg；腹腔注射) 增加在大鼠中 l-DOPA (HY-N0304) 引起的对侧转动次数[2]。 Animal Model: |
| Name | ST 1535 |
| CAS | 496955-42-1 |
| Formula | C12H16N8 |
| Molar Mass | 272.31 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Stasi MA, et al. ST 1535: a preferential A2A adenosine receptor antagonist. Int J Neuropsychopharmacol. 2006 Oct;9(5):575-84. [2]. Tronci E, et al. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol. 2007 Jul 2;566(1-3):94-102. |